|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study.
|
24508103 |
2014 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
PLA2G6 rs132985*T was associated with BRAF V600E (OR = 1.32, 95% CI = 1.05-1.67) and BRAF other (OR = 1.82, 95% CI = 1.11-2.98), but not BRAF V600K or NRAS+ melanoma.
|
29753029 |
2018 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We have evaluated five real-time ARMS assays: BRAF 1799T>A, [this includes V600E and V600K] and NRAS 182A>G [Q61R] and 181C>A [Q61K] in melanoma, EGFR 2573T>G [L858R], 2235-2249del15 [E746-A750del] in non-small-cell lung cancer, and compared the results to DNA sequencing of the mutation 'hot-spots' in these genes in formalin-fixed paraffin-embedded tumour (FF-PET) DNA.
|
20925915 |
2010 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
V600R mutation and double (V600E -V600M) mutation were identified in two melanomas.In one case, V600K mutation was found.Two screening failures were noted.
|
23463675 |
2013 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Preponderance of the oncogenic V599E and V599K mutations in the B-raf kinase domain is enhanced in melanoma lymph node metastases.
|
16179870 |
2005 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
CAST-PCR gave rapid and accurate results for the common V600E and V600K mutations, however additional assays are required to detect rarer BRAF mutation types found in 3-4% of melanomas.
|
23584600 |
2013 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
We have treated 45 patients with V600 mutated melanoma including patients with V600R mutation between July 2011 and October 2012 with the selective BRAF inhibitor dabrafenib (n=43) or vemurafenib (n=2) via a compassionate access programme.
|
23237741 |
2013 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
Significant association with old age and primary tumors of head/neck/upper back suggest chronic solar damage as a contributing factor for melanomas harboring BRAF p.V600K or class-3 mutations.
|
31277584 |
2019 |
|
melanoma
|
|
0.800 |
GeneticVariation
|
BEFREE |
The second patient had stage III BRAF V600R mutant melanoma that was treated with pembrolizumab and dabrafenib, and also developed a regressed melanocytic nevus.
|
29152725 |
2019 |
|
Metastatic melanoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were treated with the combination of dabrafenib and trametinib had significantly longer overall and progression-free survival than those treated with vemurafenib alone.
|
26433819 |
2015 |
|
Metastatic melanoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial.
|
23051966 |
2012 |
|
Metastatic melanoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Trametinib, a mitogen-activated extracellular signal-regulated kinase (MEK) inhibitor, has demonstrated great promise in treating metastatic melanoma associated with BRAF V600E and V600K mutations; however, it also is highly associated with cutaneous adverse events (AEs).
|
30489553 |
2018 |
|
Metastatic melanoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
To review and summarize data on cobimetinib, which was approved by the US Food and Drug Administration (FDA) in November 2015 for use in combination with vemurafenib for unresectable or metastatic melanoma with a BRAFV600E or V600K mutation.
|
27701080 |
2017 |
|
Metastatic melanoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
We enrolled previously untreated patients with BRAF Val600Glu or Val600Lys mutation-positive unresectable stage IIIC or stage IV melanoma.
|
26037941 |
2015 |
|
Metastatic melanoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
The aim of the present study was to investigate the frequency of the less common p.Val600Lys (V600K) mutation in metastatic melanoma from a high incidence region.
|
22614711 |
2012 |
|
Metastatic melanoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
BRAF/MEK inhibitor therapy improves outcomes in BRAF V600E- and V600K-mutated unresectable or metastatic melanoma.
|
28738051 |
2017 |
|
Metastatic melanoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma.
|
22535154 |
2012 |
|
Metastatic melanoma
|
|
0.090 |
GeneticVariation
|
BEFREE |
BRAF inhibitor activity in V600R metastatic melanoma.
|
23237741 |
2013 |
|
Neoplasm Metastasis
|
|
0.080 |
GeneticVariation
|
BEFREE |
In addition, a double mutation resulting in V599K substitution was detected in two suspect ocular metastases of cutaneous melanoma.
|
14522889 |
2003 |
|
Neoplasm Metastasis
|
|
0.080 |
GeneticVariation
|
BEFREE |
The oncogenic B-raf mutations V599E and V599K, as early events in melanocyte transformation, persist throughout metastasis with important prognostic implications.
|
16179870 |
2005 |
|
Neoplasm Metastasis
|
|
0.080 |
GeneticVariation
|
BEFREE |
Interestingly, by droplet digital PCR, the V600E mutation was also detected in the first primary, and the V600K in the second primary and metastases.
|
30222690 |
2019 |
|
Neoplasm Metastasis
|
|
0.080 |
GeneticVariation
|
BEFREE |
In melanoma, V600K mutations in comparison to other BRAF mutations were associated with more frequent brain (75% vs. 36.3%, p = 0.02) and lung metastases (91.6% vs. 47.7%, p = 0.007), and shorter time from diagnosis to metastasis and to death (19 vs. 53 months, p = 0.046 and 78 vs. 322 months, p = 0.024 respectively).
|
22039425 |
2011 |
|
Neoplasm Metastasis
|
|
0.080 |
GeneticVariation
|
BEFREE |
In this study, sensitive and quantitative BRAF V600E and V600K mutation-specific real-time quantitative PCR was used to study the occurrence of small subsets of mutation-positive cells in primary melanomas and melanoma metastases.
|
23499336 |
2013 |
|
Neoplasm Metastasis
|
|
0.080 |
GeneticVariation
|
BEFREE |
As to the B-raf protein sequence, the acidic amino acid transitions V599E and V599K were predicted in 19/60 (32%) and 6/60 (10%) cases, respectively, but were not associated with enhanced risk for subsequent metastasis in patients' follow up.
|
15935100 |
2005 |
|
Neoplasm Metastasis
|
|
0.080 |
GeneticVariation
|
BEFREE |
Mutant allele-specific imbalance of the p.V600E mutation was predominantly present in specimens with distant organ metastases (79% versus 27% in LN metastases versus 13% in primary cutaneous tumors or adjacent soft tissue, P < .001). p.V600K was detected in 23% of men older than 60 years old, compared with 6% in women older than 60 years old and 2% in both men and women younger than 60 years old (P < .001).
|
25456393 |
2015 |